A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

A Double-blind, Placebo Controlled Pharmacodynamic Study of the Effect of INCB013739 on Systemic and Adipose Tissue 11βHSD1 Activity in Obese, Insulin Resistant Subjects.

The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.

"Proprietary Information: Exploratory (Non-Confirmatory) Trial".

Inclusion Criteria:

• Male and female subjects between 18 years and 65 years of age.
• BMI between 30 and 42 kg/m2, inclusive.
• FPG <126 mg/dL

Exclusion Criteria:

• Meet criteria for diagnosis of diabetes mellitus at the screening evaluation, female subjects with a history of gestational diabetes are permitted.
• Are receiving oral antidiabetic agents within the 3 months prior to screening.